MRTX -17% (Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab) SI -12% (issues FTX-related letter) HLF -10.8% (proposed $250 mln offering of convertible notes) PSTX -4.1% (to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress) BIVI -4% (announces positive NE3107 results; filed prospectus supplement to increase shares of Class A common stock) AXON -2.2% (to offer $500 mln convertible notes in private offering) Analyst comments:
RCL -2.2% (downgraded to Underweight from Overweight at JP Morgan) CAG -1.9% (downgraded to Sell from Hold at Deutsche Bank) GIS -1.1% (downgraded to Hold from Buy at Deutsche Bank)